2024-05-16 09:50:50
«We wish to be a revolutionary drug search engine », Maximilien Levesque, co-founder, instantly shares d’Aqemia, a techbio that researches and develops medicines utilizing a singular synthetic intelligence (AI) algorithm. Eight years in the past, he co-founded Aqemia with Emmanuelle Martiano, following main a CNRS analysis group on the Ecole Normale Supérieure. “I did statistical and quantum physics of liquids on an atomic scale “. It was throughout these years of analysis that Maximilien Levesque developed a fundamental system.”I solved a mathematical equation that different scientists had been making an attempt to unravel for a very long time. A number one American drug analysis firm got here to me and provided to purchase it whereas I used to be nonetheless at ENS. », recollects the founder. Then conscious of the utility of his invention for the pharmaceutical world, Maximilien Levesque plans to make use of this know-how to develop medication in Well being.
Blends synthetic intelligence and quantum physics
«At that second I spotted that the place I’d be most helpful on the earth was in my very own firm with the know-how I had developed to create new medicines», shares the director of techbio. The next yr he participated within the ENS startup competitors, received the prize and on the similar time met Emmanuelle Martiano, a graduate of CentralSupélec and principal guide on the Boston Consulting Group, a method consulting agency, for 9 years. In 2019, he launched Aqemia along with him, between generative synthetic intelligence and nuclear physics. If AI, on the premise of the solved equation, invents molecules and energetic elements, it’s really quantum and statistical nuclear physics that corrects the propositions. “Theoretical physics performs a job as a instructor to enhance molecules powered by synthetic intelligence», explains the skilled.
Right now, there are sixty workers within the firm from all backgrounds who work every day with molecules that may give rise to drug candidates. “We’ve three molecules supposed to deal with most cancers, that are at the moment being examined on mice», enthuses the managing director of Aqemia. These options, which have achieved superb leads to the primary phases of testing, are aimed instantly at most cancers cells or are supposed to coach the immune system in order that it assaults these cells by itself. “In 4 years I used to be capable of see all of the work and progress between a mathematical system and an actual molecule decreasing the dimensions of a tumor in a mouse», helps Maximilien Levesque.
Aqemia hopes to enter the scientific trial part following preliminary conclusive outcomes
Along with its personal drug analysis and growth, Aqemia has simply signed a partnership with Sanofi for an quantity of 140 million {dollars}. “They supply the therapeutic targets, that’s, what makes sufferers sick, and we’re answerable for inventing therapeutic molecules which can be energetic on these targets.», provides the managing director of techbio. After working with the big pharmaceutical group on most cancers targets and gaining proof of the efficiency of their generative AI, the concept right this moment is to develop new analysis tasks. With this new collaboration, Aqemia expands its scope to different ailments and therapeutic areas equivalent to immunology. This partnership is along with these already entered into with Servier and Janssen.
The corporate, which has simply accomplished a funding spherical of 30 million euros, bringing the quantity raised to 60, subsequently has a vibrant future forward of it. With the ambition of getting a lot of his personal therapeutic tasks, Maximilien Levesque hopes to have the option within the close to future to have the ability to deal with incurable ailments and turn into the driving power of drug invention, a pacesetter worldwide. “We wish to enter the scientific part quickly as a result of we don’t wish to cease analysis. To be continued…», concludes the supervisor.
1715853540
#Aqemia #revolutionizing #search #therapeutic #molecules
